-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Datopotamab Deruxtecan in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Solid Tumor Drug Details: DS-1062 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RP-3 in Head And Neck Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RP-3 in Head And Neck Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RP-3 in Head And Neck Cancer Drug Details: RP-3 is...
-
Product Insights
Inhalable Drug Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Inhalable Drug Delivery Pipeline Market Report Overview An inhalable drug delivery device is meant to administer medications that are to be inhaled deeply into the lungs. Drugs are delivered either by the nasal or oral respiratory route. The Inhalable Drug Delivery pipeline market research report provides comprehensive information about the inhalable drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress. Key Segments ·       ...
-
Product Insights
Transmucosal Drug Delivery Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Transmucosal Drug Delivery Pipeline Market Report Overview A Transmucosal drug delivery device is intended for the localized delivery of medications through a mucous membrane. The transmucosal drug delivery pipeline market research report provides comprehensive information about the transmucosal drug delivery pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segment ·      Nasal ·      Vaginal ·      Buccal Delivery ·      Rectal Key Territories ·      The US...
-
Company Profile
Impel Pharmaceuticals Inc – Company Profile
Impel Pharmaceuticals Inc (Impel), formerly Impel NeuroPharma Inc, is a clinical-stage biotechnology company that develops intranasal drug treatments for central nervous system disorders. The company’s pipeline product portfolio such as Trudhesa, a liquid solution for the treatment of acute migraine; and INP105, olanzapine for the treatment of acute agitation in bipolar I disorder and schizophrenia. It also develops precision olfactory delivery technology, a nasal drug delivery platform that delivers drugs for improved biodistribution. Impel’s products are used for the treatment...
Add to Basket -
Product Insights
Net Present Value Model: Trudhesa
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Trudhesa Drug Details Dihydroergotamine mesylate (Trudhesa)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – olanzapine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry olanzapine Drug Details Olanzapine is under development for the treatment of poly ADP ribose...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – olanzapine
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry olanzapine Drug Details Olanzapine (INP-105) is under development for the treatment of agitation and...
-
Track & Monitor
Innovation in Medical Devices: Nebulizers and Atomisers
Innovations in medical devices industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in medical devices industry. Using patent data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging,...
-
Product Insights
Parkinson’s Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunctions. The main finding in brains of people with PD is loss of dopaminergic neurons in substantia nigra. Symptoms generally develop slowly over years. People with PD experience dyskinesia, dystonia, tremor, stiffness and impaired locomotory functions. Risk factors include age, genetic factors, environmental factors and gender. Treatment options include anticholinergics, COMT inhibitors and dopamine agonists. The Parkinson’s disease pipeline drugs market research report provides comprehensive information on the therapeutics under...